High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma

Hirokazu Murakami; Hiroshi Fujii; Tohru Inaba; Chihiro Shimazaki; Sinichirou Okamoto; Akiyosi Miwa; Morio Sawamura; Masahiro Abe; Takaaki Chou; Hideki Asaoku; Yoshikazu Kitahara; Kunihiko Hayashi; Masaaki Kosaka; Atsushi Togawa; Kiyoshi Takatsuki

doi:10.1111/j.1600-0609.2004.00282.x

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma

Hirokazu Murakami, Hiroshi Fujii, Tohru Inaba, Chihiro Shimazaki, Sinichirou Okamoto, Akiyosi Miwa, Morio Sawamura, Masahiro Abe, Takaaki Chou, Hideki Asaoku, Yoshikazu Kitahara, Kunihiko Hayashi, Masaaki Kosaka, Atsushi Togawa, Kiyoshi Takatsuki

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We compared the effect of high-dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta-2-microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low-risk patients in level I, and was obviously as helpful for high, as for low-risk patients in stratification II. In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients.

Original language	English
Pages (from-to)	169-173
Number of pages	5
Journal	European Journal of Haematology
Volume	73
Issue number	3
DOIs	https://doi.org/10.1111/j.1600-0609.2004.00282.x
Publication status	Published - 2004 Sept
Externally published	Yes

Keywords

Morphology
Myeloma
Prognostic factor
Stem cell transplantation
Stratification

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/j.1600-0609.2004.00282.x

Cite this

Murakami, H., Fujii, H., Inaba, T., Shimazaki, C., Okamoto, S., Miwa, A., Sawamura, M., Abe, M., Chou, T., Asaoku, H., Kitahara, Y., Hayashi, K., Kosaka, M., Togawa, A., & Takatsuki, K. (2004). High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma. European Journal of Haematology, 73(3), 169-173. https://doi.org/10.1111/j.1600-0609.2004.00282.x

Murakami, H, Fujii, H, Inaba, T, Shimazaki, C, Okamoto, S, Miwa, A, Sawamura, M, Abe, M, Chou, T, Asaoku, H, Kitahara, Y, Hayashi, K, Kosaka, M, Togawa, A & Takatsuki, K 2004, 'High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma', European Journal of Haematology, vol. 73, no. 3, pp. 169-173. https://doi.org/10.1111/j.1600-0609.2004.00282.x

@article{225d4ff438294f5bbce63c6f3ad1d838,

title = "High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma",

abstract = "We compared the effect of high-dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta-2-microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low-risk patients in level I, and was obviously as helpful for high, as for low-risk patients in stratification II. In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients.",

keywords = "Morphology, Myeloma, Prognostic factor, Stem cell transplantation, Stratification",

author = "Hirokazu Murakami and Hiroshi Fujii and Tohru Inaba and Chihiro Shimazaki and Sinichirou Okamoto and Akiyosi Miwa and Morio Sawamura and Masahiro Abe and Takaaki Chou and Hideki Asaoku and Yoshikazu Kitahara and Kunihiko Hayashi and Masaaki Kosaka and Atsushi Togawa and Kiyoshi Takatsuki",

year = "2004",

month = sep,

doi = "10.1111/j.1600-0609.2004.00282.x",

language = "English",

volume = "73",

pages = "169--173",

journal = "European Journal of Haematology",

issn = "0902-4441",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma

AU - Murakami, Hirokazu

AU - Fujii, Hiroshi

AU - Inaba, Tohru

AU - Shimazaki, Chihiro

AU - Okamoto, Sinichirou

AU - Miwa, Akiyosi

AU - Sawamura, Morio

AU - Abe, Masahiro

AU - Chou, Takaaki

AU - Asaoku, Hideki

AU - Kitahara, Yoshikazu

AU - Hayashi, Kunihiko

AU - Kosaka, Masaaki

AU - Togawa, Atsushi

AU - Takatsuki, Kiyoshi

PY - 2004/9

Y1 - 2004/9

N2 - We compared the effect of high-dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta-2-microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low-risk patients in level I, and was obviously as helpful for high, as for low-risk patients in stratification II. In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients.

AB - We compared the effect of high-dose therapy together with autologous peripheral blood stem cell transplantation (autoPBSCT) in 60 patients with multiple myeloma (MM) with 90 patients who underwent conventional chemotherapy. We scored the prognostic factors according to our reported classification system that includes measurements of serum albumin, serum beta-2-microglobulin, and morphology of myeloma cells selected by multivariate analysis. We separated the patients into three risk groups at stratification level I (low, intermediate and high) and into two risk groups at stratification level II (low and high). AutoPBSCT tended to be as effective for high, as for low-risk patients in level I, and was obviously as helpful for high, as for low-risk patients in stratification II. In conclusion, high-risk patients with MM should be treated with high-dose therapy accompanied with autoPBSCT like low-risk patients.

KW - Morphology

KW - Myeloma

KW - Prognostic factor

KW - Stem cell transplantation

KW - Stratification

UR - http://www.scopus.com/inward/record.url?scp=4043090560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043090560&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2004.00282.x

DO - 10.1111/j.1600-0609.2004.00282.x

M3 - Article

C2 - 15287913

AN - SCOPUS:4043090560

SN - 0902-4441

VL - 73

SP - 169

EP - 173

JO - European Journal of Haematology

JF - European Journal of Haematology

IS - 3

ER -

High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this